Ingesting Instead of Inhaling Could Save 60,000 Lives a Year

Chris Bunka, CEO of Lexaria Bioscience shares the company’s unique opportunity to make ingesting any number of drugs and molecules healthier with their DehydraTECH technology.

“Lexaria Bioscience has the actual opportunity of changing the world. We can do it through saving lives, making health improvements for any number of people who are ingesting any number of drugs and molecules like pain relief, cannabinoids and nicotine. Everybody knows that smoking is not healthy. Our technology allows for the delivery of drug molecules like cannabinoids or nicotine through ingesting all means. Things that you swallow and that could be a pill, could be a syrup or it could be a cup of coffee. That technology which is called the DehydraTECH is optimized to carry that drug across the intestinal wall and get more of it into your bloodstream more quickly than it otherwise could. We’ve tested it in vitro in vivo and in human clinical studies. We’re partnering with companies that can help us do it in America and elsewhere in the world. We actually have seven different R&D projects that we’re launching in the first half of 2019. We’re also continuing to work on our patent portfolio. We have 10 patents granted already and over 50 more that are pending. If we are able to help change the consumption habits of even 1 percent of the global marketplace who smoke, we could save 60,000 thousand lives a year.” – Chris Bunka, CEO of Lexaria Bioscience

Lexaria Bioscience Corp. has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:

  • Masks taste/odor
    Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
  • Reduces time of onset
    Effects are felt within 15-20 min vs. 60-120 min.
  • Avoids first-pass liver metabolism
    Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
  • Increases bio-absorption
    Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.

For more information on Lexaria Bioscience Corp. (LXX:CSE, LXRP:OTCQX) please fill out the form below.

Request Investor Kit